Table 3.
Adverse events, all grades, by number of patients experiencing the event.
| Grade | ||||||
|---|---|---|---|---|---|---|
| Adverse Event | 0 | 1 | 2 | 3 | 4 | Total |
| Leukopenia | 15 | 9 | 13 | 7 | 4 | 48 |
| Thrombocytopenia | 8 | 11 | 10 | 14 | 5 | 48 |
| Neutropenia | 19 | 9 | 10 | 6 | 4 | 48 |
| Anemia | 4 | 6 | 26 | 10 | 2 | 48 |
| Hemorrhage | 44 | 3 | 0 | 1 | 0 | 48 |
| Coagulation | 46 | 0 | 0 | 2 | 0 | 48 |
| RBC transfusion | 24 | 0 | 0 | 24 | 0 | 48 |
| Platelet transfusion | 42 | 0 | 0 | 6 | 0 | 48 |
| Nausea/vomiting | 29 | 12 | 6 | 0 | 1 | 48 |
| Gastrointestinal | 18 | 15 | 12 | 2 | 1 | 48 |
| Genitourinary | 45 | 2 | 1 | 0 | 0 | 48 |
| Alkaline phosphatase | 39 | 9 | 0 | 0 | 0 | 48 |
| SGOT | 41 | 7 | 0 | 0 | 0 | 48 |
| Alopecia | 21 | 1 | 26 | 0 | 0 | 48 |
| Dermatologic | 27 | 9 | 10 | 2 | 0 | 48 |
| Neurotoxicity | 26 | 15 | 7 | 0 | 0 | 48 |
| Renal | 45 | 3 | 0 | 0 | 0 | 48 |
| Infection | 41 | 0 | 4 | 2 | 1 | 48 |
| Fatigue | 40 | 2 | 5 | 1 | 0 | 48 |
| Pain | 22 | 14 | 11 | 1 | 0 | 48 |
| Hepatic | 38 | 6 | 3 | 1 | 0 | 48 |
| Cardiovascular/Edema | 24 | 10 | 5 | 9 | 0 | 48 |
| Metabolic | 29 | 11 | 7 | 1 | 0 | 48 |
| Lymphocytopenia | 46 | 0 | 0 | 2 | 0 | 48 |
| Fever | 43 | 2 | 1 | 2 | 0 | 48 |
| Musculoskeletal | 46 | 1 | 0 | 1 | 0 | 48 |
| Pulmonary | 36 | 4 | 4 | 3 | 1 | 48 |
| Ocular | 44 | 3 | 1 | 0 | 0 | 48 |
| Dyspnea | 47 | 0 | 1 | 0 | 0 | 48 |
| Endocrine | 45 | 3 | 0 | 0 | 0 | 48 |
| Allergy | 46 | 0 | 2 | 0 | 0 | 48 |
| Constitutional | 14 | 13 | 16 | 5 | 0 | 48 |
| DVT | 47 | 0 | 0 | 1 | 0 | 48 |
The median WBC nadir for those 33 patients experiencing leukopenia was 2200 (range: 200–3750).